{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T02:26:49Z","timestamp":1790476009758,"version":"4.1.0"},"reference-count":102,"publisher":"Elsevier BV","issue":"25","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,12,24]],"date-time":"2014-12-24T00:00:00Z","timestamp":1419379200000},"content-version":"vor","delay-in-days":388,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006010","name":"Bayer Schering","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005646","name":"Actelion Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005646","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.jacc.2013.10.026","type":"journal-article","created":{"date-parts":[[2013,12,16]],"date-time":"2013-12-16T16:21:53Z","timestamp":1387210913000},"page":"D82-D91","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":114,"special_numbering":"S","title":["New Trial Designs and Potential Therapies for Pulmonary Artery Hypertension"],"prefix":"10.1016","volume":"62","author":[{"given":"Mardi","family":"Gomberg-Maitland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd M.","family":"Bull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajeev","family":"Saggar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robyn J.","family":"Barst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amany","family":"Elgazayerly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas R.","family":"Fleming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedrich","family":"Grimminger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Rainisio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duncan J.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman","family":"Stockbridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Ventura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ardeschir H.","family":"Ghofrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lewis J.","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2013.10.026_bib1","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0009-9236(97)90160-0","article-title":"Learning versus confirming in clinical drug development","volume":"61","author":"Sheiner","year":"1997","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jacc.2013.10.026_bib2","unstructured":"The American Society for Pharmacology and Experimental Therapeutics. FDA's Bob Temple discusses strategies for successful drug trial. Available at: http:\/\/www.aspet.org\/advocacy\/fda-botanicalresearch\/strategies-for-successful-drug-trials\/. Accessed September 5, 2013."},{"key":"10.1016\/j.jacc.2013.10.026_bib3","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1093\/oxfordjournals.eurheartj.a060552","article-title":"Factorial trials in cardiology: pros and cons","volume":"15","author":"Lubsen","year":"1994","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2013.10.026_bib4","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/0895-4356(93)90163-U","article-title":"Randomized discontinuation trials: utility and efficiency","volume":"46","author":"Kopec","year":"1993","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.jacc.2013.10.026_bib5","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1513\/pats.200803-024SK","article-title":"Traditional and alternative designs for pulmonary arterial hypertension trials","volume":"5","author":"Gomberg-Maitland","year":"2008","journal-title":"Proc Am Thorac Soc"},{"key":"10.1016\/j.jacc.2013.10.026_bib6","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/S0002-8703(03)00324-7","article-title":"Active-control clinical trials to establish equivalence or noninferiority: methodological and statistical concepts linked to quality","volume":"146","author":"Gomberg-Maitland","year":"2003","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2013.10.026_bib7","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1177\/1740774511410994","article-title":"Some essential considerations in the design and conduct of non-inferiority trials","volume":"8","author":"Fleming","year":"2011","journal-title":"Clin Trials"},{"key":"10.1016\/j.jacc.2013.10.026_bib8","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/sim.2855","article-title":"Current issues in non-inferiority trials","volume":"27","author":"Fleming","year":"2008","journal-title":"Stat Med"},{"key":"10.1016\/j.jacc.2013.10.026_bib9","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.jval.2011.06.013","article-title":"Content validity\u2013establishing and reporting the evidence in newly developed patient reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force Report: part 2\u2013assessing respondent understanding","volume":"14","author":"Patrick","year":"2011","journal-title":"Value Health"},{"key":"10.1016\/j.jacc.2013.10.026_bib10","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.jval.2011.06.014","article-title":"Content validity\u2013establishing and reporting the evidence in newly developed patient reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force Report: part 1\u2013eliciting concepts for a new PRO instrument","volume":"14","author":"Patrick","year":"2011","journal-title":"Value Health"},{"key":"10.1016\/j.jacc.2013.10.026_bib11","series-title":"Clinical Measurement in Drug Evaluation","article-title":"A\u00a0regulatory authority's opinion about surrogate endpoints","author":"Temple","year":"1995"},{"key":"10.1016\/j.jacc.2013.10.026_bib12","unstructured":"U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), Center for Devices and Radiological Health (CDRH). Guidance for industry patient-reported outcome measures: use in medical product development to support labeling claims. 2009. Available at: http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM193282.pdf. Accessed September 6,\u00a02013."},{"key":"10.1016\/j.jacc.2013.10.026_bib13","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1002\/sim.5403","article-title":"Biomarkers and surrogate endpoints in clinical trials","volume":"31","author":"Fleming","year":"2012","journal-title":"Stat Med"},{"key":"10.1016\/j.jacc.2013.10.026_bib14","doi-asserted-by":"crossref","first-page":"605","DOI":"10.7326\/0003-4819-125-7-199610010-00011","article-title":"Surrogate end points in clinical trials: are we being misled?","volume":"125","author":"Fleming","year":"1996","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2013.10.026_bib15","unstructured":"National Academies Press. Evaluation of biomarkers and surrogate endpoints in chronic disease. 2010. Available at: http:\/\/www.iom.edu\/Reports\/2010\/Evaluation-of-Biomarkers-and-Surrogate-Endpoints-in-Chronic-Disease.aspx. Accessed September 5, 2013."},{"key":"10.1016\/j.jacc.2013.10.026_bib16","first-page":"H1921","article-title":"Role of endothelium-derived relaxing factor during transition of pulmonary circulation at birth","volume":"259","author":"Abman","year":"1990","journal-title":"Am J Physiol"},{"key":"10.1016\/j.jacc.2013.10.026_bib17","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1172\/JCI33338","article-title":"Persistent eNOS activation secondary to caveolin-1 deficiency induces pulmonary hypertension in mice and humans through PKG nitration","volume":"119","author":"Zhao","year":"2009","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jacc.2013.10.026_bib18","first-page":"L472","article-title":"Relative contributions of endothelial, inducible, and neuronal NOS to tone in the murine pulmonary circulation","volume":"277","author":"Fagan","year":"1999","journal-title":"Am J Physiol"},{"key":"10.1016\/j.jacc.2013.10.026_bib19","doi-asserted-by":"crossref","first-page":"13248","DOI":"10.1073\/pnas.182225899","article-title":"Adenoviral gene transfer of endothelial nitric-oxide synthase (eNOS) partially restores normal pulmonary arterial pressure in eNOS-deficient mice","volume":"99","author":"Champion","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jacc.2013.10.026_bib20","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1161\/01.CIR.93.2.266","article-title":"Role of nitric oxide in the local regulation of pulmonary vascular resistance in humans","volume":"93","author":"Cooper","year":"1996","journal-title":"Circulation"},{"issue":"Suppl I","key":"10.1016\/j.jacc.2013.10.026_bib21","first-page":"133","article-title":"Inhaled nitric oxide: its effects on pulmonary circulation and airway smooth muscle cells","volume":"14","author":"Rossaint","year":"1993","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2013.10.026_bib22","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1056\/NEJM199302113280605","article-title":"Inhaled nitric oxide for the adult respiratory distress syndrome","volume":"328","author":"Rossaint","year":"1993","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2013.10.026_bib23","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1161\/01.RES.76.2.215","article-title":"Continuous nitric oxide inhalation reduces pulmonary arterial structural changes, right ventricular hypertrophy, and growth retardation in the hypoxic newborn rat","volume":"76","author":"Roberts","year":"1995","journal-title":"Circ Res"},{"key":"10.1016\/j.jacc.2013.10.026_bib24","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/j.amjcard.2012.01.368","article-title":"Usefulness of beta-blocker therapy and outcomes in patients with pulmonary arterial hypertension","volume":"109","author":"So","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2013.10.026_bib25","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1093\/eurheartj\/ehp297","volume":"30","author":"Galie","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2013.10.026_bib26","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1053\/j.gastro.2005.10.013","article-title":"Deleterious effects of beta-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension","volume":"130","author":"Provencher","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jacc.2013.10.026_bib27","doi-asserted-by":"crossref","first-page":"H1625","DOI":"10.1152\/ajpheart.01023.2002","article-title":"Single-beat estimation of right ventricular end-systolic pressure-volume relationship","volume":"284","author":"Brimioulle","year":"2003","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.jacc.2013.10.026_bib28","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2008.11.013","article-title":"2009 focused update incorporated into the ACC\/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"53","author":"Hunt","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2013.10.026_bib29","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1253\/circj.70.1208","article-title":"Upregulated neurohumoral factors are associated with left ventricular remodeling and poor prognosis in rats with monocrotaline-induced pulmonary arterial hypertension","volume":"70","author":"Usui","year":"2006","journal-title":"Circ J"},{"key":"10.1016\/j.jacc.2013.10.026_bib30","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1164\/rccm.201003-0335OC","article-title":"Adrenergic receptor blockade reverses right heart remodeling and dysfunction in pulmonary hypertensive rats","volume":"182","author":"Bogaard","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jacc.2013.10.026_bib31","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1164\/rccm.201203-0411OC","article-title":"Dysregulated renin-angiotensin-aldosterone system contributes to pulmonary arterial hypertension","volume":"186","author":"de Man","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jacc.2013.10.026_bib32","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1161\/01.CIR.0000140724.90898.D3","article-title":"Increased sympathetic nerve activity in pulmonary artery hypertension","volume":"110","author":"Velez-Roa","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2013.10.026_bib33","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1164\/rccm.200712-1876OC","article-title":"Hyponatremia predicts right heart failure and poor survival in pulmonary arterial hypertension","volume":"177","author":"Forfia","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jacc.2013.10.026_bib34","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1161\/CIRCULATIONAHA.112.094722","article-title":"Aldosterone inactivates the endothelin-B receptor via a cysteinyl thiol redox switch to decrease pulmonary endothelial nitric oxide levels and modulate pulmonary arterial hypertension","volume":"126","author":"Maron","year":"2012","journal-title":"Circulation"},{"issue":"Suppl 2","key":"10.1016\/j.jacc.2013.10.026_bib35","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.3949\/ccjm.73.Suppl_2.S20","article-title":"Vasopressin receptor antagonists: mechanisms of action and potential effects in heart failure","volume":"73","author":"Goldsmith","year":"2006","journal-title":"Cleveland Clinic journal of medicine"},{"key":"10.1016\/j.jacc.2013.10.026_bib36","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1161\/01.CIR.82.5.1724","article-title":"Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD)","volume":"82","author":"Francis","year":"1990","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2013.10.026_bib37","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1016\/j.jacc.2012.08.959","article-title":"Effects of renal sympathetic denervation on arterial stiffness and central hemodynamics in patients with resistant hypertension","volume":"60","author":"Brandt","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2013.10.026_bib38","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.jacc.2013.05.075","article-title":"Pulmonary artery denervation to treat pulmonary arterial hypertension: a single-center, prospective, first-in-man PADN-1 study","volume":"62","author":"Chen","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2013.10.026_bib39","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/0026-0495(89)90051-6","article-title":"The pharmacology of dichloroacetate","volume":"38","author":"Stacpoole","year":"1989","journal-title":"Metabolism: clinical and experimental"},{"key":"10.1016\/j.jacc.2013.10.026_bib40","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1161\/01.RES.88.6.555","article-title":"Gene expression patterns in the lungs of patients with primary pulmonary hypertension: a gene microarray analysis","volume":"88","author":"Geraci","year":"2001","journal-title":"Circ Res"},{"key":"10.1016\/j.jacc.2013.10.026_bib41","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1161\/hc0202.101974","article-title":"Dichloroacetate, a metabolic modulator, prevents and reverses chronic hypoxic pulmonary hypertension in rats: role of increased expression and activity of voltage-gated potassium channels","volume":"105","author":"Michelakis","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2013.10.026_bib42","doi-asserted-by":"crossref","first-page":"144","DOI":"10.4103\/2045-8932.109960","article-title":"Metabolism and bioenergetics in the right ventricle and pulmonary vasculature in pulmonary hypertension","volume":"3","author":"Archer","year":"2013","journal-title":"Pulm Circ"},{"key":"10.1016\/j.jacc.2013.10.026_bib43","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1006\/jmcc.1997.0461","article-title":"Cytoplasmic redox potential affects energetics and contractile reactivity of vascular smooth muscle","volume":"29","author":"Barron","year":"1997","journal-title":"Journal of molecular and cellular cardiology"},{"key":"10.1016\/j.jacc.2013.10.026_bib44","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1161\/01.RES.0000145360.16770.9f","article-title":"Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis","volume":"95","author":"McMurtry","year":"2004","journal-title":"Circ Res"},{"key":"10.1016\/j.jacc.2013.10.026_bib45","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.1096\/fj.09-131664","article-title":"Dichloroacetate treatment partially regresses established pulmonary hypertension in mice with SM22alpha-targeted overexpression of the serotonin transporter","volume":"23","author":"Guignabert","year":"2009","journal-title":"FASEB J"},{"key":"10.1016\/j.jacc.2013.10.026_bib46","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00109-011-0804-9","article-title":"Therapeutic inhibition of fatty acid oxidation in right ventricular hypertrophy: exploiting Randle's cycle","volume":"90","author":"Fang","year":"2012","journal-title":"J\u00a0Mol Med (Berl)"},{"key":"10.1016\/j.jacc.2013.10.026_bib47","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1161\/01.CIR.93.1.135","article-title":"Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts","volume":"93","author":"McCormack","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2013.10.026_bib48","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/j.jacc.2009.01.037","article-title":"Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial","volume":"53","author":"Wilson","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2013.10.026_bib49","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1164\/ajrccm.165.4.2012112","article-title":"Chemokine RANTES in severe pulmonary arterial hypertension","volume":"165","author":"Dorfmuller","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jacc.2013.10.026_bib50","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1164\/rccm.2106007","article-title":"CX(3)C chemokine fractalkine in pulmonary arterial hypertension","volume":"165","author":"Balabanian","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jacc.2013.10.026_bib51","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1378\/chest.11-0793","article-title":"Inflammation in pulmonary arterial hypertension","volume":"141","author":"Price","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.jacc.2013.10.026_bib52","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1165\/ajrcmb.11.6.7946395","article-title":"Interleukin-1 receptor antagonist treatment reduces pulmonary hypertension generated in rats by monocrotaline","volume":"11","author":"Voelkel","year":"1994","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.jacc.2013.10.026_bib53","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1183\/09031936.00104706","article-title":"Fractalkine-induced smooth muscle cell proliferation in pulmonary hypertension","volume":"29","author":"Perros","year":"2007","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jacc.2013.10.026_bib54","first-page":"275","article-title":"Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension","volume":"144","author":"Tuder","year":"1994","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jacc.2013.10.026_bib55","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1161\/01.RES.0000201960.04223.3c","article-title":"Rho kinases in cardiovascular physiology and pathophysiology","volume":"98","author":"Loirand","year":"2006","journal-title":"Circ Res"},{"key":"10.1016\/j.jacc.2013.10.026_bib56","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.jacc.2009.04.018","article-title":"Cellular and molecular basis of pulmonary arterial hypertension","volume":"54","author":"Morrell","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2013.10.026_bib57","doi-asserted-by":"crossref","first-page":"L656","DOI":"10.1152\/ajplung.00090.2003","article-title":"Attenuation of acute hypoxic pulmonary vasoconstriction and hypoxic pulmonary hypertension in mice by inhibition of Rho-kinase","volume":"287","author":"Fagan","year":"2004","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.jacc.2013.10.026_bib58","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1161\/01.RES.0000111804.34509.94","article-title":"Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats","volume":"94","author":"Abe","year":"2004","journal-title":"Circ Res"},{"key":"10.1016\/j.jacc.2013.10.026_bib59","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1165\/ajrcmb.25.5.4461","article-title":"Rho-kinase activation is involved in hypoxia-induced pulmonary vasoconstriction","volume":"25","author":"Wang","year":"2001","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.jacc.2013.10.026_bib60","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1164\/rccm.200405-637OC","article-title":"Inhaled Rho kinase inhibitors are potent and selective vasodilators in rat pulmonary hypertension","volume":"171","author":"Nagaoka","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jacc.2013.10.026_bib61","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1161\/01.CIR.0000087592.47401.37","article-title":"Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells","volume":"108","author":"Nishimura","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2013.10.026_bib62","doi-asserted-by":"crossref","first-page":"L205","DOI":"10.1152\/ajplung.00234.2007","article-title":"Acute vasodilator effects of Rho-kinase inhibitors in neonatal rats with pulmonary hypertension unresponsive to nitric oxide","volume":"294","author":"McNamara","year":"2008","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.jacc.2013.10.026_bib63","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","article-title":"Depletion of B cells in\u00a0vivo by a chimeric mouse human monoclonal antibody to CD20","volume":"83","author":"Reff","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.jacc.2013.10.026_bib64","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","article-title":"IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma","volume":"90","author":"Maloney","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.jacc.2013.10.026_bib65","first-page":"L1047","article-title":"VIP inhibits basal and histamine-stimulated proliferation of human airway smooth muscle cells","volume":"268","author":"Maruno","year":"1995","journal-title":"Am J Physiol"},{"key":"10.1016\/j.jacc.2013.10.026_bib66","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1177\/096721090201000209","article-title":"The effects of vasoactive intestinal peptide on monocrotaline induced pulmonary hypertensive rabbits following cardiopulmonary bypass: a comparative study with isoproterenol and nitroglycerine","volume":"10","author":"Gunaydin","year":"2002","journal-title":"Cardiovasc Surg"},{"key":"10.1016\/j.jacc.2013.10.026_bib67","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1172\/JCI17500","article-title":"Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension","volume":"111","author":"Petkov","year":"2003","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jacc.2013.10.026_bib68","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1183\/09031936.00050008","article-title":"Inhalation of vasoactive intestinal peptide in pulmonary hypertension","volume":"32","author":"Leuchte","year":"2008","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jacc.2013.10.026_bib69","first-page":"A2516","article-title":"Effects of inhaled aviptadil (vasoactive intestinal peptide) in patients with pulmonary arterial hypertension (PAH)","author":"Galie","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jacc.2013.10.026_bib70","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1164\/ajrccm.185.7.786","article-title":"Vasoactive intestinal peptide in pulmonary arterial hypertension","volume":"185","author":"Said","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jacc.2013.10.026_bib71","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1056\/NEJMra044389","article-title":"Tyrosine kinases as targets for cancer therapy","volume":"353","author":"Krause","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2013.10.026_bib72","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nrd839","article-title":"Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug","volume":"1","author":"Capdeville","year":"2002","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jacc.2013.10.026_bib73","first-page":"3034","article-title":"Approval summary: imatinib mesylate in the treatment of metastatic and\/or unresectable malignant gastrointestinal stromal tumors","volume":"8","author":"Dagher","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jacc.2013.10.026_bib74","first-page":"935","article-title":"Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia","volume":"8","author":"Cohen","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jacc.2013.10.026_bib75","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1038\/nrd3297","article-title":"Targeting non-malignant disorders with tyrosine kinase inhibitors","volume":"9","author":"Grimminger","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jacc.2013.10.026_bib76","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/978-1-60761-500-2_28","article-title":"PDGF receptor and its antagonists: role in treatment of PAH","volume":"661","author":"Grimminger","year":"2010","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.jacc.2013.10.026_bib77","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1161\/CIRCULATIONAHA.112.000765","article-title":"Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study","volume":"127","author":"Hoeper","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2013.10.026_bib78","doi-asserted-by":"crossref","first-page":"702","DOI":"10.7326\/0003-4819-145-9-200611070-00015","article-title":"Terminal ballistics of kinase inhibitors: there are no magic bullets","volume":"145","author":"Maitland","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2013.10.026_bib79","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/clpt.2009.217","article-title":"A\u00a0dosing\/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension","volume":"87","author":"Gomberg-Maitland","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jacc.2013.10.026_bib80","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.taap.2009.12.032","article-title":"The cardiotoxicity and myocyte damage caused by small molecule anticancer tyrosine kinase inhibitors is correlated with lack of target specificity","volume":"244","author":"Hasinoff","year":"2010","journal-title":"Toxicology and applied pharmacology"},{"key":"10.1016\/j.jacc.2013.10.026_bib81","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1172\/JCI39434","article-title":"Cardiomyocyte PDGFR-beta signaling is an essential component of the mouse cardiac response to load-induced stress","volume":"120","author":"Chintalgattu","year":"2010","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jacc.2013.10.026_bib82","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1002\/cncr.23460","article-title":"Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor","volume":"112","author":"Khakoo","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.jacc.2013.10.026_bib83","doi-asserted-by":"crossref","first-page":"5204","DOI":"10.1200\/JCO.2007.15.6331","article-title":"Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma","volume":"26","author":"Schmidinger","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jacc.2013.10.026_bib84","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1093\/annonc\/mdn168","article-title":"Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate","volume":"19","author":"Telli","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jacc.2013.10.026_bib85","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/nrc2106","article-title":"Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition","volume":"7","author":"Force","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jacc.2013.10.026_bib86","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/S0140-6736(07)61865-0","article-title":"Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib","volume":"370","author":"Chu","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2013.10.026_bib87","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/nm1446","article-title":"Cardiotoxicity of the cancer therapeutic agent imatinib mesylate","volume":"12","author":"Kerkela","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.jacc.2013.10.026_bib88","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1161\/CIRCULATIONAHA.111.079921","article-title":"Pulmonary arterial hypertension in patients treated by dasatinib","volume":"125","author":"Montani","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2013.10.026_bib89","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1016\/j.jacc.2006.12.037","article-title":"Transplantation of autologous endothelial progenitor cells may be beneficial in patients with idiopathic pulmonary arterial hypertension: a pilot randomized controlled trial","volume":"49","author":"Wang","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2013.10.026_bib90","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1161\/01.RES.0000157672.70560.7b","article-title":"Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells: efficacy of combined cell and eNOS gene therapy in established disease","volume":"96","author":"Zhao","year":"2005","journal-title":"Circ Res"},{"key":"10.1016\/j.jacc.2013.10.026_bib91","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.jacc.2007.10.041","article-title":"Interventricular mechanical asynchrony in pulmonary arterial hypertension: left-to-right delay in peak shortening is related to right ventricular overload and left ventricular underfilling","volume":"51","author":"Marcus","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2013.10.026_bib92","doi-asserted-by":"crossref","first-page":"H2196","DOI":"10.1152\/ajpheart.00870.2009","article-title":"Right ventricular free wall pacing improves cardiac pump function in severe pulmonary arterial hypertension: a computer simulation analysis","volume":"297","author":"Lumens","year":"2009","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.jacc.2013.10.026_bib93","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1093\/europace\/eur189","article-title":"Right ventricular pacing improves haemodynamics in right ventricular failure from pressure overload: an open observational proof-of-principle study in patients with chronic thromboembolic pulmonary hypertension","volume":"13","author":"Hardziyenka","year":"2011","journal-title":"Europace"},{"key":"10.1016\/j.jacc.2013.10.026_bib94","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/01.MAT.0000151922.67540.E9","article-title":"Extracorporeal life support registry report 2004","volume":"51","author":"Conrad","year":"2005","journal-title":"ASAIO J"},{"key":"10.1016\/j.jacc.2013.10.026_bib95","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1164\/rccm.201109-1599OC","article-title":"Extracorporeal membrane oxygenation in awake patients as bridge to lung transplantation","volume":"185","author":"Fuehner","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jacc.2013.10.026_bib96","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.healun.2011.03.002","article-title":"Impact of extracorporeal life support on outcome in patients with idiopathic pulmonary arterial hypertension awaiting lung transplantation","volume":"30","author":"de Perrot","year":"2011","journal-title":"J\u00a0Heart Lung Transplant"},{"key":"10.1016\/j.jacc.2013.10.026_bib97","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1111\/j.1600-6143.2010.03192.x","article-title":"Extracorporeal membrane oxygenation in nonintubated patients as bridge to lung transplantation","volume":"10","author":"Olsson","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jacc.2013.10.026_bib98","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1016\/j.athoracsur.2011.03.002","article-title":"Use of bicaval dual-lumen catheter for adult venovenous extracorporeal membrane oxygenation","volume":"91","author":"Javidfar","year":"2011","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jacc.2013.10.026_bib99","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.jtcvs.2011.10.061","article-title":"Venovenous extracorporeal membrane oxygenation using a single cannula in patients with pulmonary hypertension and atrial septal defects","volume":"143","author":"Javidfar","year":"2012","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jacc.2013.10.026_bib100","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/j.1600-6143.2009.02549.x","article-title":"Bridge to thoracic organ transplantation in patients with pulmonary arterial hypertension using a pumpless lung assist device","volume":"9","author":"Strueber","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jacc.2013.10.026_bib101","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.healun.2010.03.010","article-title":"Ethical issues associated with globalization of placebo-controlled in pulmonary arterial hypertension","volume":"29","author":"Farber","year":"2010","journal-title":"J\u00a0Heart Lung Transplant"},{"key":"10.1016\/j.jacc.2013.10.026_bib102","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.healun.2010.03.009","article-title":"Editor's response to \u201cethical issues associated with globalization of placebo-controlled trials in pulmonary arterial hypertension.\u201d","volume":"29","author":"Park","year":"2010","journal-title":"J\u00a0Heart Lung Transplant"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109713058695?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109713058695?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:04:14Z","timestamp":1760015054000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109713058695"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":102,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S0735109713058695"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2013.10.026","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New Trial Designs and Potential Therapies for Pulmonary Artery Hypertension","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2013.10.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}